Improvement In Metabolic Co-Morbidities After Implantation Of Cardiomems In Patients With Heart Failure With Preserved Ejection Fraction Phenotype

Introduction Heart failure with preserved ejection fraction (HFpEF) patient population often have other comorbidities including obesity, dyslipidemia, hypertension and diabetes comprising the metabolic syndrome. The impacts of hemodynamic monitoring via Cardiomems on these co-morbidities remains unknown. Methods A retrospective analysis of 29 patients with HFpEF (EF 45% or greater) with Cardiomems was reviewed at a single center. Weight, body mass index (BMI), systolic blood pressures (SBP), high-density lipoprotein (HDL), triglycerides (TGL), hemoglobin A1C (HA1C), and pulmonary artery diastolic pressures (PADP) were assessed at baseline and six months post implant. Paired t-tests and the Wilcoxon signed-rank test were used as appropriate to test differences between time points. Results Twenty nine patients, 31% male, 62% NICM, mean age of 73 years were analyzed. At time of Cardiomems implantation, average weight was 102.55 kgs ± 22.70, BMI was 38.01 kg/m^2 ± 8.30, SBP was 135 mmHg ± 19, HDL was 42.4 mg/dl ± 11.3, TGL was 150.5 mg/dl ± 60.3, and PADP was 20.10 mmHg ± 5.72. At six month follow-up, with a decrease by 21% in PADP to 15.86 ± 5.76, (p =  Conclusion The addition of controlling PADP with Cardiomems implantation results in improvement in the comorbidities associated with the metabolic syndrome. Further studies are warranted to validate these findings and delineate clinical significance on a patient\u0027s quality of life.